Sensenonics Shares Are Trading Higher After the Company Announced FDA Clearance for Its Next-generation Eversense 365 Continuous Glucose Monitoring (CGM) System for People With Type 1 and Type 2 Diabetes Aged 18 Years Older.
Sensenonics Shares Are Trading Higher After the Company Announced FDA Clearance for Its Next-generation Eversense 365 Continuous Glucose Monitoring (CGM) System for People With Type 1 and Type 2 Diabetes Aged 18 Years Older.
瑞思諾公司的股票交投較高，因爲該公司宣佈其新一代Eversense 365持續血糖監測（CGM）系統獲得FDA批准，適用於18歲及以上的1型和2型糖尿病患者。
Sensenonics Shares Are Trading Higher After the Company Announced FDA Clearance for Its Next-generation Eversense 365 Continuous Glucose Monitoring (CGM) System for People With Type 1 and Type 2 Diabetes Aged 18 Years Older.
Sensenonics宣佈其適用於18歲以上的1型和2型糖尿病患者的下一代Eversense 365連續血糖監測（CGM）系統獲得美國食品藥品管理局的批准，此後，該公司股價走高。
資訊熱榜
更新時間